{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"283.123","value":"265.09"},{"groupId":"OG001","spread":"323.891","value":"326.16"}]}],"title":"Baseline (n:198, 195)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"183.010","value":"243.03"},{"groupId":"OG001","spread":"377.752","value":"326.78"}]}],"title":"Cycle 2 Day 1 (n: 185, 184)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"268.582","value":"280.18"},{"groupId":"OG001","spread":"286.154","value":"292.27"}]}],"title":"Cycle 3 Day 1 (n: 185, 174)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"326.634","value":"283.51"},{"groupId":"OG001","spread":"325.409","value":"319.60"}]}],"title":"Cycle 4 Day 1 (n: 171, 159)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set (FAS) consists of all patients who were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1","title":"Plasma Angiogenesis Marker: Vascular Endothelial Growth Factor (VEGF)","type":"SECONDARY","unitOfMeasure":"pg/mL"}